- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00484874
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
One third of patients with Hodgkin's lymphoma (HL) do not respond to or have their disease come back after their first therapy. These patients often then receive high-dose chemotherapy and blood or marrow transplant. Despite high response rates after transplant, a significant number, 26-65%, of these patients have their disease come back again. After transplant, therapy options are limited and alternative therapies for patients with HL who have relapsed post-transplant or who are ineligible for transplant are needed. Based on recent studies about how HL develops and good results of patient studies evaluating the use of the unlabeled anti-CD20 antibody Rituximab in HL, we think that radioimmunotherapy (RIT) with I-131 Tositumomab(Bexxar®) will be an effective alternative therapy in patients with relapsed/refractory HL who are post or ineligible for transplant.
The rationale for the use of RIT in cancer is that radiolabeled monoclonal antibodies will specifically target and irradiate tumor cells but not normal tissues. The specific tumor targeting of RIT theoretically allows higher doses of radiation to be delivered to tumor as compared to external beam radiation because the effects of the radiation on normal tissues is less with RIT. Iodine-131 Tositumomab (Bexxar®) was approved by the FDA for another type of lymphoma in 2003. The antibody (Tositumomab) recognizes and attaches to a protein on lymphoma cells and can kill these cells. The radioisotope (I-131) can help the antibody kill cells better.
Iodine-131 Tositumomab (Bexxar®) is given through a vein in the arm. Iodine-131 Tositumomab (Bexxar®) is given in an outpatient setting.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Medical Institutions
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Biopsy-proven Hodgkin's lymphoma that is relapsed or refractory and the patient has previously had a transplant or is ineligible for transplant
- All stages and histologic subtypes of Hodgkin's lymphoma
- Malignant cells may be CD20+ or CD20-
- May have previously had either a non-myeloablative or myeloablative allogeneic or autologous stem cell transplant
- If prior history of greater than 1 transplant, eligible if other entry criteria are met
- No upper limit on the amount of prior chemotherapy
- Must be at least 4 weeks out from their most recent chemotherapy or radiation therapy, 6 weeks if the last regimen included BCNU, or mitomycin
- Age 18 or greater
- Karnofsky performance status ≥ 60
- Organ and marrow function within 4 weeks of registration on the protocol as defined below:
- Leukocytes >2,000/mm3
- Absolute neutrophil count >1,000/ mm3
- Platelets >75,000/ mm3
- Hemoglobin >7 g/dL
- Creatinine <2.5 mg/dL
- Less than 25% bone marrow involvement with Hodgkin's lymphoma within 4 weeks of registration on the protocol
- If female, not pregnant or breast feeding
- Ability to understand and the willingness to sign a written informed consent document
- At least one measurable target lesion, measuring 1.5 cm in at least one dimension by standard CT imaging which is FDG -avid on PET/CT.
- 2-year expected survival from other diseases
Exclusion Criteria:
- Receiving any other investigational agents at the same time
- Hypocellular bone marrow (less than or equal to 10% cellularity) or marked decrease in any one (or more) hematopoietic precursor within 4 weeks of registration on the protocol
- Inability to follow basic radiation safety precautions
- Active infections requiring intravenous antibiotics until after resolution of the infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A Single Dose of I-131 Tositumomab
I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.
|
Tositumomab and I-131 tositumomab are given intravenously.
A test dose is given followed by a larger treatment dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-myeloablative Maximum Tolerated Dose of I-131 Tositumomab That Can be Given to Patients With Relapsed/Refractory Hodgkin's Lymphoma.
Time Frame: 2 years
|
2 years
|
|
Overall and Complete Response Rates
Time Frame: 12 weeks post therapy
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CTI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
12 weeks post therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Time to Progression Following I-131 Tositumomab Therapy.
Time Frame: From time measurement criteria are met for response until first date that recurrent or progressive disease is objectively documented, assessed up to 5 years.
|
From time measurement criteria are met for response until first date that recurrent or progressive disease is objectively documented, assessed up to 5 years.
|
|
Frequency of Visualization of Hodgkin's Lymphoma With I-131 Tositumomab Imaging and Tumor Radiation Absorbed Dose
Time Frame: up to 1 week post-intervention
|
Percentage of participants with visualized I-131 uptake.
|
up to 1 week post-intervention
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Richard L Wahl, MD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- J0703
- NA_00005743 (Other Identifier: JHM IRB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin's Disease
-
University Hospital, BrestCompletedDiagnostic Imaging | Relapsed Non Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult | Malignant Lymphoma
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedLymphoma | Hodgkin's Lymphoma | Hodgkin DiseaseUnited States
-
Bayside HealthCompletedNon-Hodgkin's Lymphoma | Hodgkin's DiseaseAustralia
-
Hospital JP GarrahanHospital Pereyra Rosell, Montevideo, UruguayRecruitingPediatric Hodgkin's DiseaseArgentina
-
Bayside HealthCompletedNon-Hodgkin's Lymphoma | Hodgkin's DiseaseAustralia
-
National Cancer Institute (NCI)CompletedNon Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; MedImmune...CompletedLymphoma | Non-Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
Baylor College of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); The Methodist... and other collaboratorsRecruitingLymphoma | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Lymphoproliferative DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedTransplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line MobilizationNetherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
-
Spectrum Pharmaceuticals, IncCompletedNon-Hodgkins Lymphoma | Tumors | Hodgkins DiseaseUnited States, Canada
Clinical Trials on I-131 Tositumomab therapeutic regimen
-
GlaxoSmithKlineCompleted
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | Lymphoid Leukemia in RemissionUnited States
-
GlaxoSmithKlineCompletedLymphoma, Non-HodgkinUnited States, France, United Kingdom
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
University of Michigan Rogel Cancer CenterGlaxoSmithKlineActive, not recruitingMultiple MyelomaUnited States
-
Rush University Medical CenterGlaxoSmithKline; Millennium Pharmaceuticals, Inc.Terminated
-
GlaxoSmithKlineCompletedNon-Hodgkin's LymphomaUnited States